Repertoire Immune Medicines

About:

Repertoire Immune Medicines is a clinical stage biotechnology company.

Top Investors: Invus, Alaska Permanent Fund, SoftBank Vision Fund, PSP Investments, JDRF T1D Fund

Description:

Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Total Funding Amount:

$257M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2015-01-01

Founders:

Bart Henderson, Ewen Cameron, Noubar Afeyan, Thomas Lars Andresen, Ulrik Nielsen

Number of Employees:

51-100

Last Funding Date:

2021-04-13

IPO Status:

Private

Industries: